Minzasolmin (UCB0599, (R)-NPT200-11) is an orally active, blood-brain-permeable alpha-synuclein (alpha-Syn) inhibitor that selectively binds to alpha-Syn misfolded intermediates (such as oligomers) and inhibits aggregation and fibril formation by regulating their conformational stability. Minzasolmin can reduce the generation of pathological oligomers and block neurotoxic signaling, thereby reducing the abnormal accumulation of alpha-Syn in the brain. Minzasolmin significantly improved motor deficits, reduced neuroinflammatory markers, and alpha-Syn-related pathological deposition in transgenic mouse models[1][2].
Molecular Weight:
425.59
Purity:
98.60
CAS Number:
[1802518-92-8]
Formula:
C23H31N5OS
Target:
alpha-synuclein
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted